Publications

Abstract Insulin is the major endocrine hormone responsible for regulating whole-body glucose homeostasis by regulating glucose uptake in insulin-sensitive tissue. Obesity is one of the main factors initiating the development of insulin resistance through increased adipose tissue size, inflammation, and ectopic fat deposition in insulin-sensitive tissues. Inflammation and fat accumulation are key drivers for losing […]

Abstract Insulin is the major endocrine hormone responsible for regulating whole-body glucose homeostasis by regulating glucose uptake in insulin-sensitive tissue. Obesity is one of the main factors initiating the development of insulin resistance through increased adipose tissue size, inflammation, and ectopic fat deposition in insulin-sensitive tissues. Inflammation and fat accumulation are key drivers for losing […]

Abstract Insulin is the major endocrine hormone responsible for regulating whole-body glucose homeostasis by regulating glucose uptake in insulin-sensitive tissue. Obesity is one of the main factors initiating the development of insulin resistance through increased adipose tissue size, inflammation, and ectopic fat deposition in insulin-sensitive tissues. Inflammation and fat accumulation are key drivers for losing […]

Abstract Insulin is the major endocrine hormone responsible for regulating whole-body glucose homeostasis by regulating glucose uptake in insulin-sensitive tissue. Obesity is one of the main factors initiating the development of insulin resistance through increased adipose tissue size, inflammation, and ectopic fat deposition in insulin-sensitive tissues. Inflammation and fat accumulation are key drivers for losing […]

Abstract Insulin is the major endocrine hormone responsible for regulating whole-body glucose homeostasis by regulating glucose uptake in insulin-sensitive tissue. Obesity is one of the main factors initiating the development of insulin resistance through increased adipose tissue size, inflammation, and ectopic fat deposition in insulin-sensitive tissues. Inflammation and fat accumulation are key drivers for losing […]

Abstract Anti-obesity medications have reached new heights in terms of efficacy, with presently available pharmacological options almost reaching the efficacy of the surgical techniques, and thus these are starting to fill the treatment void. Because of the increased weight loss efficacy, benefits on a host of obesity complications are being reported, with prevention of diabetes, […]

Abstract Metabolic dysfunction-associated steatohepatitis (MASH) is a common but frequently unrecognized complication of obesity and type 2 diabetes. The association between these conditions is multifaceted and involves complex interactions between metabolic, inflammatory, and genetic factors. Here we assess the underlying structural and molecular processes focusing on the immunological phase of MASH in the nonobese inflammation […]

Abstract BACKGROUND AND OBJECTIVES Dual amylin and calcitonin receptor agonists (DACRAs) are therapeutic candidates in the treatment of obesity with beneficial effects on weight loss superior to suppression of food intake. Hence, suggesting effects on energy expenditure by possibly targeting mitochondria in metabolically active tissue. METHODS Male rats with HFD-induced obesity received a DACRA, KBP-336, […]

Abstract Long-acting dual amylin and calcitonin receptor agonists (DACRAs) are novel candidates for the treatment of type 2 diabetes and obesity due to their beneficial effects on body weight, glucose control, and insulin action. However, how the metabolic benefits are maintained after long-lasting treatment is unknown. This study investigates the long-term anti-obesity and anti-diabetic treatment […]

Abstract OBJECTIVE Dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonists are therapeutic agents with an interesting liver-specific mode of action suitable for metabolic complications. In this study, dual GLP-1 and glucagon receptor agonist OXM-104 is compared head-to-head with the once-daily dual GLP-1 and glucagon receptor agonist cotadutide and GLP-1 receptor agonist semaglutide to explore the […]